Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials

被引：0
|
作者：
Lars-Erik Kristensen [1 ]
Dennis McGonagle [2 ]
Martin Rudwaleit [3 ]
Hideto Kameda [4 ]
Peter Adler Würtzen [5 ]
Marcus Ngantcha [5 ]
Thorsten Holzkämper [5 ]
Josef Smolen [6 ]
机构：
[1] The Parker Institute,Rheumatology
[2] Bispebjerg and Frederiksberg Hospital,Department of Internal Medicine
[3] Leeds Institute of Rheumatic and Musculoskeletal Medicine,Department of Rheumatology
[4] University of Bielefeld,undefined
[5] Toho University,undefined
[6] Eli Lilly and Company,undefined
[7] Vienna General Hospital,undefined
[8] University of Vienna,undefined
来源：
Rheumatology and Therapy | 2025年 / 12卷 / 2期
关键词：
Psoriatic arthritis; Enthesitis; Axial disease; Dactylitis; Peripheral arthritis; Skin psoriasis; Nail psoriasis; Health-related quality of life;
D O I：
10.1007/s40744-025-00748-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：381 / 395
页数：14
相关论文
共 50 条
  • [21] Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
    Gladman, Dafna
    Coates, Laura
    Wu, Joseph
    Fallon, Lara
    Hsu, Ming-Ann
    Bushmakin, Andrew
    Bacci, Elizabeth
    Cappelleri, Joseph
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
    Dafna D. Gladman
    Laura C. Coates
    Joseph Wu
    Lara Fallon
    Elizabeth D. Bacci
    Joseph C. Cappelleri
    Andrew G. Bushmakin
    Philip S. Helliwell
    Arthritis Research & Therapy, 24
  • [23] ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS
    Gossec, L.
    Mease, P. J.
    Gottlieb, A. B.
    Ogdie, A.
    Assudani, D.
    Coarse, J.
    Ink, B.
    Coates, L. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1683 - 1683
  • [24] Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
    Orbai, Ana-Maria
    Gladman, Dafna D.
    Birt, Julie
    Gellett, Amanda M.
    Lin, Chen-Yen
    Kvien, Tore
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [25] Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
    Orbai, A-M
    Gladman, D. D.
    Goto, H.
    Birt, J. A.
    Gellett, A. M.
    Lin, C-Y
    Kvien, T. K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 329 - 336
  • [26] Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients
    Lo Monaco, Marika
    Bocchio, Raffaella Mallaci
    Natoli, Giuseppe
    Giardina, Annarita
    Cangemi, Ignazio
    Scibetta, Salvatore
    Argano, Christiano
    Corrao, Salvatore
    FRONTIERS IN MEDICINE, 2024, 10
  • [27] Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
    Ana-Maria Orbai
    Julie A. Birt
    Elizabeth A. Holdsworth
    Nicola Booth
    William N. Malatestinic
    Aubrey T. Sprabery
    Anthony M. Reginato
    Rheumatology and Therapy, 2020, 7 : 937 - 948
  • [28] Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
    Orbai, Ana-Maria
    Birt, Julie A.
    Holdsworth, Elizabeth A.
    Booth, Nicola
    Malatestinic, William N.
    Sprabery, Aubrey T.
    Reginato, Anthony M.
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 937 - 948
  • [29] Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis
    Gossec, Laure
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E159 - E160
  • [30] Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Wei, C. -C.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 566 - 574
12345